From the ∗Premier Health Urgent Care, Baton Rouge, LA
†Visby Medical, Inc., San Jose, CA
‡No Resistance Consulting Group, LLC, Birmingham, AL
§Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
Conflict of Interest and Sources of Funding: MD, LB, KD, GH, and CAG received research funding from Visby Medical, Inc. All other authors declared no potential conflicts of interest.
This study was funded by Visby Medical, San Jose, CA. CAG was supported by National Institutes of Health (NIH) (U54EB007958, National Institute of Biomedical Imaging and Bioengineering, NIH; U-01 068613, National Institute of Allergy and Infectious Diseases, NIH; R01AI138978, National Institute of Allergy and Infectious Diseases, NIH).
Correspondence: Gary Schoolnik, MD, Visby Medical, Inc., 3010 North First St., San Jose, CA 95314. E-mail: [email protected].
Received for publication September 10, 2021, and accepted November 13, 2021.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (http://www.stdjournal.com).
